Format

Send to

Choose Destination
Clin Rheumatol. 2017 Jun;36(6):1215-1220. doi: 10.1007/s10067-017-3588-7. Epub 2017 Mar 1.

A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?

Author information

1
University of Massachusetts Medical School, Worcester, MA, USA. Leslie.Harrold@umassmed.edu.
2
Corrona, LLC, Southborough, MA, USA. Leslie.Harrold@umassmed.edu.
3
Corrona, LLC, Southborough, MA, USA.
4
Bristol-Myers Squibb, Princeton, NJ, USA.
5
Albany Medical College and The Center for Rheumatology, Albany, NY, USA.

Abstract

The objective of the study was to examine whether disease duration independently predicts treatment response among biologic-naïve patients with rheumatoid arthritis (RA) initiating abatacept in clinical practice. Using the Corrona RA registry (February 2006-January 2015), biologic-naïve patients with RA initiating abatacept with 12-month (±3 months) follow-up and assessment of disease activity (Clinical Disease Activity Index [CDAI]) at initiation and at 12 months were identified. The primary outcome was mean change in CDAI (ΔCDAI) from baseline to 12 months. Secondary outcomes at 12 months included achievement of low disease activity (LDA; CDAI ≤10 in patients with moderate/high disease activity at initiation) and remission (CDAI ≤2.8 in patients with low, moderate or high disease activity at initiation). Linear and logistic regression analyses were performed to examine the relationship between disease duration and response to abatacept. There were 281 biologic-naïve patients with RA initiating abatacept (disease duration 0-2 years, n = 107; 3-5 years, n = 45; 6-10 years, n = 50; >10 years, n = 79). Increased disease duration was associated with older age (p = 0.047), and the median number of prior conventional disease-modifying antirheumatic drugs used was lowest in the 0- to 2-year duration group (p < 0.001). Mean ΔCDAI (SE) ranged from -10.22 (1.19) for 0-2 years to -4.63 (1.38) for >10 years. In adjusted analyses, shorter disease duration was significantly associated with greater mean ΔCDAI (p = 0.015) and greater likelihood of achieving LDA (p = 0.048). In biologic-naïve patients with RA initiating abatacept, earlier disease (shorter disease duration) was associated with greater ΔCDAI and likelihood of achieving LDA.

KEYWORDS:

Disease activity; Disease-modifying antirheumatic drugs (DMARDs); Non-TNFi biologic; Outcome measures; Registry; Rheumatoid arthritis

PMID:
28251392
PMCID:
PMC5486472
DOI:
10.1007/s10067-017-3588-7
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center